Macquarie University has officially opened a $96 million RNA Research and Manufacturing Facility, marking a major milestone in Australia's biomedical and biotechnology capability and strengthening New South Wales' preparedness for future health challenges.
Located within the Macquarie University Innovation Precinct, the facility positions NSW at the forefront of RNA research and manufacturing and supports the development of next‑generation vaccines, therapeutics and treatments across human and animal health.
Macquarie University has officially opened a $96 million RNA Research and Manufacturing Facility. Picture: Chris Barlow
The facility is the only site in Australia capable of producing a wide range of RNA therapeutics. Providing advanced laboratories and support spaces that enable innovations to progress from research through to small‑scale manufacturing and clinical readiness.
Macquarie University Vice‑Chancellor Professor Bruce S Dowton said the facility comes at a pivotal moment for biomedical science globally.
"Macquarie University is proud to host this new RNA facility and to help bring it to life at a time of extraordinary global momentum in biomedical science," Professor Dowton said.
"RNA technologies are transforming how we understand, prevent and treat disease, with the potential to reshape healthcare for generations to come.
"This facility will play a vital role in strengthening Australia's capabilities in this critical field, while also adding to a thriving medical and research precinct here at Macquarie Park."
Strengthening national capability and preparedness
The facility reinforces Macquarie Park's position as Australia's largest and most connected biomedical precinct, home to universities, hospitals, global technology companies and research organisations working across health, life sciences and advanced manufacturing.
The facility will support faster responses to emerging diseases while attracting investment, creating local jobs and fostering collaboration between universities, research institutes, and industry.
Industry partner and operator Aurora BioSynthetics will work with researchers and clients to help advance RNA innovations from laboratory discovery towards clinical trials and commercial application.
Beyond vaccines, RNA technologies have diverse applications, including treatments for cancer and rare genetic diseases, as well as agricultural and biosecurity solutions.
Translating research into impact
Macquarie University researchers and clinicians are already working on some of the most urgent medical and biosecurity challenges of our time—areas where RNA research holds significant promise.
Professor Dowton said the University is committed to supporting the collaboration and translation required to ensure RNA innovation delivers tangible benefits.
"We are honoured to be the home of this important work, and to support the collaboration, innovation and translation needed to deliver real‑world impact for patients, communities and the health system," he said.
The opening of the RNA Research and Manufacturing Facility marks a significant step forward for Macquarie University, NSW and Australia—strengthening national capability, accelerating biomedical innovation and ensuring critical infrastructure is in place before the next global health challenge emerges.
